GUERBET : Revenue at June 30, 2016: €376.7 million, up 65.7%
July 28 2016 - 11:45AM
Change
in pro forma revenue*: - 5.3%
Change in pro forma revenue* at constant exchange rates: - 2.3%
Villepinte, July
28, 2016 - Guerbet (FR0000032526 GBT), a
global specialist in contrast agents and solutions for medical
imaging, is reporting revenue of €376.7 million for the
1st half of
2016, up 65.7% from 2015. This increase incorporates an adverse
exchange rate impact of €11.9 million, mainly on the Brazilian
real, Argentine peso, Korean won, and the Turkish lira. At constant
exchange rates, the Group posted sales of €388.6 million, slightly
down 2.3% from the pro forma revenue for the first half of
2015.
Consolidated Group revenue
(IFRS)
In millions of € |
1st half 2016 |
|
1st half
2015
pro forma* |
Change |
|
1st half 2015
reported |
Change |
Sales - Europe |
189,7 |
|
187,5 |
+1.2% |
|
158,7 |
+19.5% |
Sales - Other
Markets |
187,0 |
|
210,3 |
-11,1% |
|
68,6 |
+172.6% |
Total |
376,7 |
|
397,8 |
-5,3% |
|
227,3 |
+65.7% |
*: Integration of
CMDS activities
Good performance
level in Europe
In Europe, consolidated revenue for the first half totaled €189.7
million compared with €187.5 million for 2015 in its pro forma
version, incorporating an adverse exchange rate impact of nearly €2
million. At current exchange rates, the second quarter confirmed
the growth of the first quarter, which was already 1.2%.
Outside Europe, despite the good
performance of Dotarem® in the US,
the Group's sales totaled €187.0 million compared with €210.3
million for 2015 in its pro forma version, an 11.1% decrease.
However, this decline incorporates an adverse exchange rate impact
of nearly €10 million and reveals an improving trend in the second
quarter (-9.0%), at current exchange rates, compared with the first
quarter (-13.1%).
Double-digit
growth in Dotarem® sales,
lower performance for X-rays
At constant exchange rates, the activity breaks down as
follows:
-
good Dotarem sales in both Europe and the US
resulted in half-year revenue of €121.8 million for MRI, up 5.5%
-
the X-ray segment fell by
6.8% to €205.3 million, mainly due to Optiray, but its decline
began to slow down in the second quarter thanks to stimulus actions
undertaken since the acquisition of CMDS
-
the performance of Lipiodol® and
Patent Blue V increased the IRT segment's
revenue by 18.3% to €25.4 million
-
lastly, the Imaging Solutions
and Services (ISS) segment is down nearly
7.4% with revenue of €34.5 million, reflecting lower injector
sales.
2016 outlook:
stabilization of sales at +/- 3% already achieved and confirmation
of annual targets
The second quarter confirms Guerbet's ability to reverse the trend
on sharply declining CMDS sales (-20% over the last two years
before the acquisition). At the end of the first half, consolidated
sales are -2.3% at constant exchange rates, within the target
window of +/- 3% announced for the full year. The Group is
therefore confirming its annual targets and its ability to start
growing again in 2017.
Upcoming
events:
Publication of
2016 half-year earnings: September 28, 2016, before trading
Guerbet is a pioneer in the
contrast agent field, with nearly 90 years' experience, and is the
only pharmaceutical group dedicated to medical imaging worldwide.
It offers a comprehensive range of X-Ray, Magnetic Resonance
Imaging (MRI), and Interventional Radiology and Theranostics (IRT)
products, along with a range of injectors and related medical
devices to improve the diagnosis and treatment of patients. To
discover new products and ensure future growth, Guerbet invests
heavily in R&D, spending around 9% of its sales each year.
Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps)
and generated revenue of €489 million in
2015.
For more information about Guerbet,
please visit www.guerbet.com
Jean-François Le Martret
Chief Financial Officer
01 45 91 50 00
|
Financial Communications
Benjamin Lehari
01 56 88 11 25
blehari@actifin.fr
Press
Jennifer Jullia
01 56 88 11 19
jjullia@actifin.fr
|
Press release
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
HUG#2031561
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024